Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection - United Kingdom
doi 10.1016/j.cmi.2018.11.010
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Reducing Harm in the Treatment of Multidrug-Resistant Tuberculosis

The Lancet
Medicine
2018English

Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2004English

Multidrug Resistant Tuberculosis

British Medical Journal
Medicine
2015English

P56 Treatment of Multidrug Resistant Tuberculosis: Where Are the Guidelines for Monitoring?

Thorax
PulmonaryRespiratory Medicine
2011English

The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis

New England Journal of Medicine
Medicine
2009English

Hepatotoxicity During Treatment for Multidrug-Resistant Tuberculosis: Occurrence, Management and Outcome

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2012English

Rifabutin: Is It Useful in the Treatment of Multidrug-Resistant Tuberculosis?

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy